Zn(2+) site engineering at the oligomeric interface of the dopamine transporter

Kristine Norgaard-Nielsen; Lene Norregaard; Hanne Hastrup; Jonathan A Javitch; Ulrik Gether

Zn(2+) site engineering at the oligomeric interface of the dopamine transporter

Kristine Norgaard-Nielsen, Lene Norregaard, Hanne Hastrup, Jonathan A Javitch, Ulrik Gether

33 Citationer (Scopus)

Abstract

Increasing evidence suggests that Na(+)/Cl(-)-dependent neurotransmitter transporters exist as homo-oligomeric proteins. However, the functional implication of this oligomerization remains unclear. Here we demonstrate the engineering of a Zn(2+) binding site at the predicted dimeric interface of the dopamine transporter (DAT) corresponding to the external end of transmembrane segment 6. Upon binding to this site, which involves a histidine inserted in position 310 (V310H) and the endogenous Cys306 within the same DAT molecule, Zn(2+) potently inhibits [(3)H]dopamine uptake. These data provide indirect evidence that conformational changes critical for the translocation process may occur at the interface between two transporter molecules in the oligomeric structure.

Originalsprog	Engelsk
Tidsskrift	FEBS Letters
Vol/bind	524
Udgave nummer	1-3
Sider (fra-til)	87-91
Antal sider	5
ISSN	0014-5793
Status	Udgivet - 31 jul. 2002

Citationsformater

@article{7a60edcdc7ec47e083d61e59caadd0a6,

title = "Zn(2+) site engineering at the oligomeric interface of the dopamine transporter",

abstract = "Increasing evidence suggests that Na(+)/Cl(-)-dependent neurotransmitter transporters exist as homo-oligomeric proteins. However, the functional implication of this oligomerization remains unclear. Here we demonstrate the engineering of a Zn(2+) binding site at the predicted dimeric interface of the dopamine transporter (DAT) corresponding to the external end of transmembrane segment 6. Upon binding to this site, which involves a histidine inserted in position 310 (V310H) and the endogenous Cys306 within the same DAT molecule, Zn(2+) potently inhibits [(3)H]dopamine uptake. These data provide indirect evidence that conformational changes critical for the translocation process may occur at the interface between two transporter molecules in the oligomeric structure.",

keywords = "Animals, Biopolymers, COS Cells, Dopamine, Dopamine Plasma Membrane Transport Proteins, Humans, Membrane Glycoproteins, Membrane Transport Proteins, Mutagenesis, Site-Directed, Nerve Tissue Proteins, Polymerase Chain Reaction, Protein Binding, Zinc",

author = "Kristine Norgaard-Nielsen and Lene Norregaard and Hanne Hastrup and Javitch, {Jonathan A} and Ulrik Gether",

year = "2002",

month = jul,

day = "31",

language = "English",

volume = "524",

pages = "87--91",

journal = "F E B S Letters",

issn = "0014-5793",

publisher = "JohnWiley & Sons Ltd",

number = "1-3",

}

TY - JOUR

T1 - Zn(2+) site engineering at the oligomeric interface of the dopamine transporter

AU - Norgaard-Nielsen, Kristine

AU - Norregaard, Lene

AU - Hastrup, Hanne

AU - Javitch, Jonathan A

AU - Gether, Ulrik

PY - 2002/7/31

Y1 - 2002/7/31

N2 - Increasing evidence suggests that Na(+)/Cl(-)-dependent neurotransmitter transporters exist as homo-oligomeric proteins. However, the functional implication of this oligomerization remains unclear. Here we demonstrate the engineering of a Zn(2+) binding site at the predicted dimeric interface of the dopamine transporter (DAT) corresponding to the external end of transmembrane segment 6. Upon binding to this site, which involves a histidine inserted in position 310 (V310H) and the endogenous Cys306 within the same DAT molecule, Zn(2+) potently inhibits [(3)H]dopamine uptake. These data provide indirect evidence that conformational changes critical for the translocation process may occur at the interface between two transporter molecules in the oligomeric structure.

AB - Increasing evidence suggests that Na(+)/Cl(-)-dependent neurotransmitter transporters exist as homo-oligomeric proteins. However, the functional implication of this oligomerization remains unclear. Here we demonstrate the engineering of a Zn(2+) binding site at the predicted dimeric interface of the dopamine transporter (DAT) corresponding to the external end of transmembrane segment 6. Upon binding to this site, which involves a histidine inserted in position 310 (V310H) and the endogenous Cys306 within the same DAT molecule, Zn(2+) potently inhibits [(3)H]dopamine uptake. These data provide indirect evidence that conformational changes critical for the translocation process may occur at the interface between two transporter molecules in the oligomeric structure.

KW - Animals

KW - Biopolymers

KW - COS Cells

KW - Dopamine

KW - Dopamine Plasma Membrane Transport Proteins

KW - Humans

KW - Membrane Glycoproteins

KW - Membrane Transport Proteins

KW - Mutagenesis, Site-Directed

KW - Nerve Tissue Proteins

KW - Polymerase Chain Reaction

KW - Protein Binding

KW - Zinc

M3 - Journal article

C2 - 12135746

SN - 0014-5793

VL - 524

SP - 87

EP - 91

JO - F E B S Letters

JF - F E B S Letters

IS - 1-3

ER -

Zn(2+) site engineering at the oligomeric interface of the dopamine transporter

Abstract

Fingeraftryk

Citationsformater